Newsroom

OAKVILLE, Ontario--(BUSINESS WIRE)--Suite au récent communiqué de presse daté du 12 décembre 2025, (Groupe de portefeuilles Harvest Inc. « Harvest ») est heureuse de fournir des mises à jour supplémentaires concernant le dépôt d’un prospectus préliminaire auprès des autorités canadiennes en valeurs mobilières pour le FNB Harvest Rendement supérieur des banques canadiennes (« HPYB ») et le FNB Harvest Rendement supérieur amélioré (« HPYE »). HPYB offre aux investisseurs l'accès à un portefeuille...

OAKVILLE, Ontario--(BUSINESS WIRE)--Following the recent press release dated December 12, 2025, Harvest Portfolios Group Inc. (“Harvest”) is pleased to provide additional updates to the filing of a preliminary prospectus with the Canadian securities regulators for the Harvest Premium Yield Canadian Bank ETF (“HPYB”) and the Harvest Premium Yield Enhanced ETF (“HPYE”). HPYB provides investors access to a Canadian Banks equity portfolio seeking long-term capital appreciation, on a levered basis,...

NEW YORK--(BUSINESS WIRE)--General American Investors Company, Inc. (NYSE: GAM), a closed-end investment company, announced that the price at which shares of its common stock will be issued to stockholders who elected to receive additional shares in payment of the 2025 year-end dividend and distribution on its common stock will be $58.745 per share. The issue price represents the average between the high and the low prices on the New York Stock Exchange on December 12, 2025, which was below the...

MIAMI--(BUSINESS WIRE)--FAIRHOLME FUNDS, INC. THE FAIRHOLME FUND (FAIRX) On December 12, 2025, the Fairholme Fund (NASDAQ: FAIRX) distributed an Ordinary Income dividend of $0.22209 per share to shareholders of record as of December 11, 2025. The Fairholme Fund’s Net Asset Value (“NAV”) was reduced by the total amount of the distribution. The Record Date, Ex-Dividend Date, Payable Date, and Cents-Per-Share are as follows: Distribution Type Record Date Ex-Dividend Date Payable Date Cents-Per-Sha...

HOUSTON--(BUSINESS WIRE)--Halliburton Company (NYSE: HAL) will host a conference call on Wednesday, January 21, 2026, to discuss its fourth quarter 2025 financial results. The call will begin at 8:00 a.m. CT (9:00 a.m. ET). The Company will issue a press release regarding the fourth quarter 2025 earnings prior to the conference call. The press release will be posted on the Halliburton website at www.halliburton.com. Please visit the Halliburton website to listen to the call via live webcast. A...

LOS ANGELES--(BUSINESS WIRE)--Glancy Prongay & Murray LLP, a leading national shareholder rights law firm, today announced that it has commenced an investigation on behalf of Fermi Inc. (“Fermi” or the “Company”) (NASDAQ: FRMI) investors concerning the Company’s possible violations of the federal securities laws. IF YOU ARE AN INVESTOR WHO LOST MONEY ON FERMI (FRMI), CLICK HERE TO INQUIRE ABOUT POTENTIALLY PURSUING CLAIMS TO RECOVER YOUR LOSS. What Happened? On October 1, 2025, Fermi began...

TORONTO--(BUSINESS WIRE)--Granite Real Estate Investment Trust (“Granite” or the “Trust”) (TSX: GRT.UN / NYSE: GRP.U) announced today that the last day of trading for Granite’s trust units ("Units") on the New York Stock Exchange ("NYSE") is expected to be December 31, 2025. Granite has filed an application for its Units to be quoted on the OTCQX platform, operated by OTC Markets Group Inc., and expects trading to begin on or about January 2, 2026. Unitholders will not be required to exchange t...

CHICAGO--(BUSINESS WIRE)--OFS Credit Company, Inc. (Nasdaq: OCCI) (“OFS Credit”, the “Company”, “we”, “us” or “our”), an investment company that primarily invests in collateralized loan obligation (“CLO”) equity and debt securities, today announced the following net asset value (“NAV”) estimate at November 30, 2025. Management’s unaudited estimate of the range of our NAV per share of our common stock at November 30, 2025 is between $5.01 and $5.11. This estimate is not a comprehensive statement...

DUBLIN--(BUSINESS WIRE)--The "Non-Opioid Therapeutics Market - Global Forecast 2025-2032" has been added to ResearchAndMarkets.com's offering. This market research report focuses on the evolving landscape of the Non-Opioid Therapeutics Market. This sector has grown from USD 40.77 billion in 2024 to USD 43.78 billion in 2025, with projections suggesting a CAGR of 7.68% leading to a valuation of USD 73.72 billion by 2032. Non-opioid therapeutics have become critical in modern pain management, add...

WALTHAM, Mass.--(BUSINESS WIRE)--Innoviva Specialty Therapeutics, a subsidiary of Innoviva, Inc. (NASDAQ: INVA), today announced that the U.S. Food and Drug Administration (FDA) has approved NUZOLVENCE® (zoliflodacin) for oral suspension, a first-in-class, single-dose oral medication for the treatment of uncomplicated urogenital gonorrhea in adults and pediatric patients 12 years and older weighing at least 35 kg. The development of NUZOLVENCE was part of a private, not-for-profit collaboration...